New hope for low blood counts after CAR T-Cell therapy?
NCT ID NCT06285825
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This study tests a drug called emapalumab to see if it can safely help people whose blood cell counts stay dangerously low after CAR T-cell therapy for certain lymphomas. About 32 adults who have already received standard CAR T-cell therapy will take part. The goal is to find out if emapalumab can improve blood cell recovery and reduce complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Time infusion of Dual-Target CAR-T cells outsmart resistant blood cancers?
- New study aims to unlock the secrets of Children's rare blood diseases
- New hope for hard-to-treat lymphoma: experimental drug combo enters phase 3 trial
- New combo offers hope for aggressive lymphoma in diverse patients
- Can a cancer drug stop a blood disorder before it turns deadly?
- Experimental cocktail aims to tackle tough lymphoma